Searchable abstracts of presentations at key conferences in endocrinology

ea0022p615 | Neuroendocrinology and Pituitary (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

Lanreotide-ATG effectiveness on tumoral mass shrinkage of two thyrotropin-secreting pituitary macroadenomas

Paniagua Amalia , Bernabeu Ignacio , Marazuela Monica

Context: There is scant evidence of tumoral mass reduction in Thyrotropin-secreting pituitary adenomas (TSPA) treated with long-acting somatostatin analogs. There are no reports that evaluate TSPA shrinkage after deep subcutaneous (sc) Lanreotide-ATG (L-ATG) therapy.Objective: The primary objective was to observe if L-ATG could reduce TSPA tumor mass.Methods: A literature review on the subject was made. The biochemical and radiolog...

ea0056p858 | Pituitary - Clinical | ECE2018

Consensus on the management of acromegaly in Spain

Bernabeu Ignacio , Camara Rosa , Marazuela Monica , Domingo Manel Puig

Objective: To find consensus on issues that may raise clinical doubts in the management of patients with acromegaly in Spain.Methods: Nominal group and Delphi methodology was followed. Four experts on acromegaly were selected, who defined important clinical questions in the management of acromegaly. A set recommendations were proposed to solve these questions. Subsequently, a group of 30 additional endocrinologits from all over Spain was selected accordi...

ea0035p731 | Neuroendocrinology | ECE2014

Influence of the exon 3 deletion of GH receptor and IGF1 level at diagnosis on the efficacy and safety of treatment with somatotropin in adults with GH deficiency

Andujar-Plata Paula , Fernandez-Rodriguez Eva , Quinteiro Celsa , Casanueva Felipe , Bernabeu Ignacio

Introduction: Human recombinant growth hormone (hrGH) treatment in adult patients with GH deficiency (GHD) has an important interindividual variability and several factors can influence it. The aims of the study were: i)- to analyze the genotype of GHR regarding exon 3 deletion (d3-GHR) in a serie of adult patients with GHD; ii)- to assess the effect of d3-GHR on initial IGF1 levels; iii)- to evaluate if d3-GHR and/or initial IGF1 levels were associated with adverse effects an...

ea0026p258 | Pituitary | ECE2011

Prevalence of germline mutations of AIP gene in sporadic aggressive somatotropinomas

Puig-Domingo M , Oriola J , Halperin I , Mora M , Diaz-Soto G , Perales M J , Alvarez-Escola C , Lucas-Morante T , Bernabeu Ignacio , Marazuela Monica

Most kindreds of familial isolated pituitary adenomas (FIPA) with mutated AIP develop somatotropinomas, characterized by an aggressive clinical phenotype including early age at diagnosis, large tumours and frequent invasiveness. In non-family cases, the prevalence of AIP mutations in pituitary adenomas is lower than 10%. There is no information of AIP prevalence in isolated somatotropinomas characterized by poor response to conventional treatment.Aim: To...

ea0022p625 | Neuroendocrinology and Pituitary (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

Efficacy and safety of co-administration of lanreotide Autogel 120 mg monthly with pegvisomant weekly in patients with acromegaly partially controlled by somatostatin analogues

van der Lely Aart-Jan , Bernabeu Ignacio , Cap Jan , Caron Philippe , Colao Annamaria , Lesage Catherine , Marek Josef , Neggers Sebastian , Birman Pascal

Recent studies have shown that the co-administration of lanreotide (lan) with pegvisomant (peg) was able to normalise IGF1 secretion in patients with acromegaly who were partial responders to somatostatin analogues (SSAs).Fifty seven subjects with acromegaly (mean age 51.6±12.7 years) not previously controlled by SSAs (either treated by SSAs for at least 6 months with IGF1 > ULN, or on peg for at least 3 months) with IGF1 > 1.2 ULN (n...

ea0040oc1 | (1) | ESEBEC2016

A new chemotherapy combination (U0126+SN50) potentiates apoptosis in thyroid cancer but induced survival in normal thyroid

Rodrigues Joana S , Garcia-Rendueles Angela R , Garcia-Rendueles Maria E R , Farina Maria Suarez , Perez-Romero Sihara , Bernabeu Ignacio , Rodriguez-Garcia Javier , Fugazzola Laura , Sakai Toshiyuki , Liu Fang , Cameselle-Teijeiro Jose , Bravo Susana B , Alvarez Clara V

Papillary thyroid carcinoma (PTC), the most frequent thyroid cancer, has low proliferation but no apoptosis, presenting frequent lymph-node metastasis (Ordonez et al., 2004).SMAD3 has two opposite phosphorylation sites: the TGF-βRI–induced C-terminal Serine SMAD3 phosphorylation and the phosphorylation induced by CDK2 (T8, T179 and S213) and ERK (T179, S204, S208) (Wang et al. 2005, Matsuura et al. 2005).<p class=...

ea0056gp11 | Acromegaly | ECE2018

Observational, multicentre study to evaluate the effectiveness in routine clinical practice of Lanreotide Autogel 120 mg at extended dosing intervals (>4 weeks) for the treatment of acromegaly: SOMACROL study

Escola Cristina Alvarez , Fajardo Carmen , Marazuela Monica , Carballido Fernando Cordido , Venegas Eva Maria , Velasco Pedro de Pablos , Maroto Gonzalo Piedrola , Marquez Ma del Pilar Olvera , de Paz Isabel Pavon , Carvalho Davide , Romero Carme , De la Cruz Guillermo , Bernabeu Ignacio

Background: Acromegaly is usually caused by a benign pituitary tumour, with increased production of growth hormone (GH) and insulin-like growth factor 1 (IGF-1). Treatment options include surgery, followed by pharmacological treatment with dopamine agonists, somatostatin analogues, GH receptor antagonists or radiotherapy. Treatment optimization is important to decrease the burden of this often-chronic disease on the patient.Objectives: To evaluate the ef...

ea0073aep521 | Pituitary and Neuroendocrinology | ECE2021

Outcomes and complications of endoscopic pituitary surgery: A single-center study

Taibo Rocio Villar , Alicia Santamaría Nieto , Paula Andújar Plata , Antía Fernández Pombo , María Gemma Rodríguez Carnero , Ignacio Bernabeu Morón

ObjectivesTo present the results of our series of endoscopic surgery of PA, performed in a third level hospital by an experienced team.MethodsRetrospective review of PA undergoing endoscopic surgery between 2011 – 2018 in our institution. Clinical variables and radiological characteristics and outcomes were collected at diagnosis, before surgery and for an average of 4.8 years of postoperative follow-up....

ea0081p166 | Pituitary and Neuroendocrinology | ECE2022

Pasireotide imaging study: magnetic resonance imaging as a predictor of therapeutic response in acromegaly

Ruiz Sabina , Venegas Moreno Eva , Gil Joan , CAMARA ROSA , Biagetti Betina , Angeles Galvez Moreno Maria , Maraver Silvia , Gonzalez-Molero Inmaculada , Pico-Alfonso Antonio , Abellan Galiana Pablo , trincado pablo , Teresa Herrera Arranz Maria , Olvera Pilar , Xifra Villarroya Gemma , Bernabeu Ignacio , Azriel Mira Sharona , Garcia-GarciA-Doncel Lourdes , Jorda Mireia , Valassi Elena , Puig-Domingo Manel

Background: T2-weighted magnetic resonance imaging (MRI) signal has been recently linked with a better tumor response to pasireotide treatment in patients with acromegaly (ACRO). Our aim was to evaluate the prevalence of this radiological feature and its association to therapeutic outcomes in a large cohort of ACRO patients treated with pasireotide.Methods: A retrospective multicentre study was performed in 15 Spanish tertiary university hospitals includ...

ea0090p401 | Pituitary and Neuroendocrinology | ECE2023

Mortality in acromegaly diagnosed in the elderly in Spain is higher in women compared to the general Spanish population

Biagetti Betina , Iglesias Pedro , Villar Taibo Rocio , Dolores Moure Maria , Paja Fano Miguel , Araujo Castro Marta , Ares Blanco Jessica , Cristina Alvarez Escola Maria , Vicente Almudena , Alvarez Guivernau Elia , Novoa-Testa Iria , Cordido Carballido Fernando , Camara-Gomez Rosa , Lecumberri Beatriz , Garcia Gomez Carlos , Bernabeu Ignacio , Manjon Miguelez Laura , Gaztambide Sonia , Webb Susan , Luis Menendez Torre Edelmiro , Jose Diez Juan , Simo Canonge Rafael , Puig-Domingo Manel

Context: There is no data on mortality of acromegaly diagnosed in the elderly. Objective: To compare clinical characteristics, GH-related comorbidities, therapeutic approaches and mortality of patients diagnosed before or after 2010 and to assess overall mortality compared with the general Spanish population. Setting: Spanish tertiary care centers.Design, Patients, and Methods: Retrospective evaluation of 118...